Ultrasound developer Esaote, based in Genoa, Italy, has signed a letter of intent for a three-year technical and commercial cooperation agreement with Hitachi Medical. Pending regulatory approvals, the two firms will collaborate on new ultrasound
Ultrasound developer Esaote, based in Genoa, Italy, has signed a letter of intent for a three-year technical and commercial cooperation agreement with Hitachi Medical. Pending regulatory approvals, the two firms will collaborate on new ultrasound products and exchange technical information and components. Each company will continue to independently develop and market its existing product lines.
Both firms highlighted new ultrasound units at Decembers RSNA conference. Esaote introduced Technos, a premium ultrasound device designed for abdominal, ob/gyn, vascular, small parts, breast, and urology imaging, while Tarrytown, NY-based Hitachi unveiled Hitachi 6000, a work-in-progress unit that includes tissue harmonic imaging, directional CFA, and artifact suppression algorithms (SCAN 12/15/99 and 1/12/00).
In other Esaote news, the company released preliminary financial results for fiscal year 1999 (end-December), posting consolidated sales of $196.8 million, up 11% from 1998s $176.2 million. Sales in dedicated MRI climbed more than 60%, from $13.5 million in 1998 to $21.5 million in 1999, while the companys ultrasound sales were $112.7 million, up from $106.6 million the year before.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.